Drugs / TBA-354
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02606214 | Nov → Dec 2015 | tuberculosis | Global Alliance for TB Drug Development | Terminated | No outcome recorded |
| Phase 1 | NCT02288481 | Jan → Jun 2015 | tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-03-11 | Global Alliance for TB Drug Development | Results Phase 1 Clinical Trial of TB Drug Candidate TBA-354 Discontinued tballiance.org ↗
Based on the observed side effects and pharmacokinetic data of TBA-354 generated in this cohort, TB Alliance together with its scientific advisors made the decision to stop the clinical trial and the clinical development program of TBA-354. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-03-11 | Global Alliance for TB Drug Development | Phase 1 Clinical Trial of TB Drug Candidate TBA-354 Discontinued tballiance.org ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBA-354 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02288481 ↗ |
| Modality | Small molecule | — CHEMBL1630563 ↗ |
| Route | Oral | “for oral administration” NCT02288481 ↗ |